Latest report on Hepatitis C Drugs Industry of 113 pages now added by a leading business intelligence provider to MarketReportsOnline.com database.
Pune, Maharashtra -- (SBWIRE) -- 03/15/2017 -- The hepatitis C market is rapidly evolving as new launches prompt a significant paradigm shift in the treatment of the disease. In 2011, a breakthrough in HCV therapy was witnessed with the first two direct acting anti-HCV drugs (Incivek and Victrelis) came to market and were followed by the market approval of two additional anti-HCV drugs (Sovaldi and Olysio) in 2013. These new drugs have significantly improved HCV cure rates. Hepatitis C virus drug market is expected to nearly quadruple of its current figure by 2014. The world market for HCV drugs represents an area of potential opportunities in developed as well as developing countries. Because of the technological advancements and effectiveness, many big market players are focusing on development of innovative drugs for HCV. Major companies are forming coalitions and agreements to develop effective treatment on Hepatitis C virus. The Hepatitis C (HCV) market is entering a new stage due to the emergence of treatment innovations. The HCV market is expected to have the best growth opportunities over the coming decade.
Hepatitis C (hep C) is a viral disease caused by the Hepatitis C virus (HCV) and transmitted by blood, primarily in health care settings. It can progressively damage the liver, and, if left untreated, cause liver cirrhosis, liver cancer, and death. Hep C is the leading cause of liver cancer and liver transplants. In addition, the virus is associated with a variety of conditions beyond liver disease, including diabetes and depression. In July 2013, the World Health Organization (WHO) estimated that over 150 Million people are chronically infected worldwide. The annual number of deaths due to HCV is estimated at 350,000 globally, or nearly 1,000 per day. The HCV pandemic is concentrated in middle-income countries (MICs); while 15% of the 150 million people with chronic HCV live in High income countries (HICs), 73% live in middle-income countries (MICs) and 12% in low-income countries (LICs).
Scope of Report
This research report provides an extensive analysis of the Hepatitis C Drugs Market and Forecast (2009 - 2019). The report covers historical analysis of Hepatitis C Approved Drugs from (2009 - 2013), along with forecast figures for (2014 - 2019). The report covers forecasted value of Hepatitis C - Pipeline Drugs Sales from (2014 - 2019). The report provides a detailed analysis of 9 Companies Hepatitis C Pipeline Drugs - Clinical Trials. The report gives an insight on the Hepatitis C Deals and Acquisitions (2004 - 2014)
Purchase This Report at http://www.marketreportsonline.com/contacts/purchase.php?name=481200.
Worldwide - Hepatitis C Drugs Market and Pipeline Drugs Analysis to 2019 provides an in-depth analysis of the drugs, pipeline drugs and the key players that will shape the future of Hepatitis C Drugs Market. This 113 page report enriched with 27 Figures and 1 Table studies the Hepatitis C Drug Market Landscape. This Report is analyzed from four view points: Approved drugs sales, Pipeline drugs sales, Company Wise Clinical Trial Analysis and Deals and Acquisitions in Hepatitis C Landscape.
Company Wise - Hepatitis C Pipeline Drugs Clinical Trials: Roche, AbbVie, Gilead Sciences, Achillion, Merck, Tibotec / Janssen, Bristol-Myers Squibb (BMS), Vertex & Genentech
Major Points from Table of Contents:
1. Executive Summary
2. Hepatitis C Drugs Market and Forecast
3. Hepatitis C - Approved Drugs Sales and Forecast to 2019
3.1 Pegylated Interferon
3.2.1 Intron A
3.3 Nucleoside Analogs (Ribavirin)
3.4 Protease Inhibitor
3.4.1 Victrelis (Boceprevir)
3.4.2 Johnson and Johnson Incivek (Telaprevir)
3.4.3 Vertex Incivek (Telaprevir
3.4.4 Olysio (Simeprevir/TMC435)
3.4.5 Sovaldi (Sofosbuvir / GS-7977)
3.4.6 Daklinza (Daclatasvir/BMS-790052)
4. Hepatitis C - Pipeline Drugs Sales and Forecast to 2019
4.1 HCV Franchise (Bristol-Myers Squibb)
4.2 HCV Franchise (AbbVie)
4.3 PEG-Interferon Lambda
4.5 MK-8742 + MK-5172
4.6 Mericitabine or RG7128
4.7 Sunvepra (Asunaprevir)
4.8 ABT-450/r + Ombitasvir (ABT-267) + Dasabuvir (ABT-333)
5. Hepatitis C - Deals and Acquisitions
6. Hepatitis C - Company Wise Pipeline Drugs Clinical Trials Analysis
Browse All Latest Pharmaceuticals Market Research Reports at www.marketreportsonline.com/cat/pharmaceuticals-market-research.html.
MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
2nd Floor, Metropole,
Next to Inox Theatre,
Bund Garden Road,
Pune - 411001.
Tel: + 1 888 391 5441